Model-Based Tacrolimus Follow-up Dosing in Adult Renal Transplant Recipients: A Simulation Trial
- 25 March 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 44 (5) , 606-614
Abstract
Background: Initial algorithm-based dosing appears to be effective in predicting tacrolimus dose requirement. However, achieving and maintaining the target concentrations is challenging. Model-based follow-up dosing, which considers patient characteristics and pharmacological data, may further personalize treatment. This study investigated whether model-based follow-up dosing could lead to more accurate tacrolimus exposure than standard therapeutic drug monitoring (TDM) in kidney transplant recipients after an initial algorithm-based dose. Methods: This simulation trial included patients from a prospective trial that received an algorithm-based tacrolimus starting dose followed by TDM. For every measured tacrolimus predose concentration (C0,obs), model-based dosing advice was simulated using the InsightRX software. Based on previous tacrolimus doses and C0, age, body surface area, CYP3A4 and CYP3A5 genotypes, hematocrit, albumin, and creatinine, the optimal next dose, and corresponding tacrolimus concentration (C0,pred) were predicted. Results: Of 190 tacrolimus C0 values measured in 59 patients, 121 (63.7%; 95% CI 56.8–70.5) C0,obs were within the therapeutic range (7.5–12.5 ng/mL) versus 126 (66.3%, 95% CI 59.6–73.0) for C0,pred (P = 0.89). The median absolute difference between the tacrolimus C0 and the target tacrolimus concentration (10.0 ng/mL) was 1.9 ng/mL for C0,obs versus 1.6 ng/mL for C0,pred. In a historical cohort of 114 kidney transplant recipients who received a body weight–based starting dose followed by TDM, 172 of 335 tacrolimus C0 (51.3%) were within the therapeutic range (10.0–15.0 ng/mL). Conclusions: The combination of an algorithm-based tacrolimus starting dose with model-based follow-up dosing has the potential to minimize under- and overexposure to tacrolimus in the early posttransplant phase, although the additional effect of model-based follow-up dosing on initial algorithm-based dosing seems small.Keywords
This publication has 23 references indexed in Scilit:
- Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipientsExpert Opinion on Drug Metabolism & Toxicology, 2015
- Total plasma protein effect on tacrolimus elimination in kidney transplant patients – Population pharmacokinetic approachEuropean Journal of Pharmaceutical Sciences, 2014
- Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant PatientsTherapeutic Drug Monitoring, 2014
- Inclusion of CYP 3 A 5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantationTransplant International, 2013
- Importance of hematocrit for a tacrolimus target concentration strategyEuropean Journal of Clinical Pharmacology, 2013
- Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipientsPharmacogenetics and Genomics, 2013
- Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism – a prospective, randomized, controlled studyClinical Transplantation, 2013
- Dosing equation for tacrolimus using genetic variants and clinical factorsBritish Journal of Clinical Pharmacology, 2011
- Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant RecipientsClinical Pharmacology & Therapeutics, 2009
- Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patientsBritish Journal of Clinical Pharmacology, 2007